Evaluation for Potential Drug-Drug Interaction of MT921 Using In Vitro Studies and Physiologically-Based Pharmacokinetic Models

• 主要な著者: Hyo-jeong Ryu (著者), Hyun-ki Moon (著者), Junho Lee (著者), Gi-hyeok Yang (著者), Sung-yoon Yang (著者), Hwi-yeol Yun (著者), Jung-woo Chae (著者), Won-ho Kang (著者)
• フォーマット: 図書
• 出版事項: MDPI AG, 2021-07-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

MT921 is a new injectable drug developed by Medytox Inc. to reduce submental fat. Cholic acid is the active pharmaceutical ingredient, a primary bile acid biosynthesized from cholesterol, endogenously produced by liver in humans and other mammals. Although individuals treated with MT921 could be adm...